WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy
Caris Life Sciences | April 11, 2022
Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used to treat metastatic colorectal cancer (CRC). These results will be presented at the 2022 American ...
Curi Bio Inc. | December 30, 2021
Curi Bio Inc., a leading developer of human stem cell-based platforms for drug discovery, announced the second closing of a $10 million oversubscribed Series A financing. New investors include UTC Investment and DS Asset Management, joining current Curi Bio investor and Series A lead Dynamk Capital. The investment will be used to scale Curi’s existing business and accelerate the development of its innovative engineered tissue analysis platforms, including its Mantarray™ platform.
MedTech, Industrial Impact
Puma Biotechnology | December 08, 2022
Puma Biotechnology, Inc. a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster entitled “Neratinib and ado-Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases Translational Breast Cancer Research Consortium Trial 022,” was presented by Rachel A Freedman, MD, MPH, Breast Oncology Center, Susan F. Smith Center for Wome...
Enzychem Lifesciences | March 03, 2022
Enzychem Lifesciences a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee. Composed of four eminent physicians, its mission is to support and guide corporate activities including technology transfer for its lead compound, EC-18, seeking strategic partnerships, and preparing U.S. phase 3 clinical trials to successfully commercialize EC-18.
After the completion of its phase 2 U.S. clinical trial with EC-18 in Chemoradiation&ndash...
Industrial Impact, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE